Andrew I. I. Schafer

Dr. Andrew I. I. Schafer

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2014 in Blood
Verified
Journal Article
Open access
PDF file
RLRichard J. Lin
Richard J. Lin
VAVahid Afshar-Kharghan
Vahid Afshar-Kharghan
ASAndrew I. I. Schafer
Andrew I. I. Schafer
Paraneoplastic thrombocytosis is associated with many solid tumors and often correlates with reduced survival. Recent studies suggest that a pathogenic feed back loop may be operative between platelets and tumor cells, with reciprocal interactions between tumor growth/metastasis and thrombocytosis/platelet activation. Specific molecular pathways have been identified in which tumors can stimulate platelet production and activation; activated platelets can, in turn, promote tumor growth and metastasis. Taken together, these findings provide exciting new potential targets for therapeutic intervention.

22 April 2021 in Blood
Verified
Journal Article
Closed access
PDF file
Hans HasselbalchHans Hasselbalch
Hans Hasselbalch
MEMargitta Elvers
Margitta Elvers
ASAndrew I. I. Schafer
Andrew I. I. Schafer
Thrombotic, vascular, and bleeding complications are the most common causes of morbidity and mortality in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). In these disorders, circulating red cells, leukocytes and platelets, as well as some vascular endothelial cells (ECs), each have abnormalities that are cell-intrinsic to the MPN driver mutations they harbor (e.g. JAK2 V617F). When these cells are activated in the MPNs, their interactions with each other create a highly pro-adhesive and prothrombotic milieu in the circulation that predisposes MPN patients to venous, arterial, and microvascular thrombosis and occlusive disease. Bleeding problems in the MPNs are caused by the MPN blood cell-initiated development of acquired von Willebrand disease. The inflammatory state created by MPN stem cells in their microenvironment extends systemically to amplify the clinical thrombotic tendency and, at the same time, preferentially promote further MPN stem cell clonal expansion, thereby generating a vicious cycle that favors a prothrombotic state in these diseases.

1 January 2010 in Translational Research
Verified
Journal Article
Closed access
ASAndrew I. I. Schafer
Andrew I. I. Schafer

1 April 2021 in Hematology/Oncology Clinics of North America
Verified
Journal Article
Closed access
ASAndrew I. I. Schafer
Andrew I. I. Schafer

12 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAndrew I. I. Schafer
Andrew I. I. Schafer
DMDouglas L Mann
Douglas L Mann
The most common causes of morbidity and mortality in the myeloproliferative neoplasms (MPNs), with the exception of myelofibrosis, are venous and arterial thrombosis, as well as more recently discovered cardiovascular disease (CVD). Clonal hematopoiesis of indeterminate potential (CHIP) is the subclinical finding in an individual of somatic mutations that are also found in clinically overt MPNs and other myeloid malignancies. The prevalence of “silent” CHIP increases with age. CHIP can transform into a clinically overt MPN at an estimated rate of 0.5 to 1% per year. It is likely, therefore, but not proven, that many, if not all, MPN patients had antecedent CHIP, possibly for many years. Moreover, both individuals with asymptomatic CHIP, as well as clinically diagnosed patients with MPN, can develop thrombotic complications. An unexpected and remarkable discovery during the last few years is that even CHIP (as well as MPNs) are significant, independent risk factors for CVD. This review discusses up-to-date information on the types of thrombotic and cardiovascular complications that are found in CHIP and MPN patients. A systemic inflammatory state (that is often subclinical) is most likely to be a major mediator of adverse reciprocal bone marrow–cardiovascular interplay that may fuel the development of progression of MPNs, including its thrombotic and vascular complications, as well as the worsening of cardiovascular disease, possibly in a “vicious cycle”. Translating this to clinical practice for hematologists and oncologists who treat MPN patients, attention should now be paid to ensuring that cardiovascular risk factors are controlled and minimized, either by the patient’s cardiologist or primary care physician or by the hematologist/oncologist herself or himself. This review is intended to cover the clinical aspects of thrombosis and cardiovascular complications in the MPN, accompanied by pathobiological comments.

2 April 2009 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
AKAmit N. Keswani
Amit N. Keswani
KPKelly Peyton
Kelly Peyton
WDWilliam Durante
William Durante
ASAndrew I. I. Schafer
Andrew I. I. Schafer
DTDavid Tulis
David Tulis
Guanosine-specific cyclic nucleotide signaling is suggested to serve protective actions in the vasculature; however, the influence of selective pharmacologic modulation of cyclic guanosine monophosphate— synthesizing soluble guanylate cyclase or cyclic guanosine monophosphate—degrading phosphodiesterase on vessel remodeling has not been thoroughly examined. In this study, rat carotid artery balloon injury was performed and the growth-modulating effects of the soluble guanylate cyclase stimulator YC-1 or the cyclic guanosine monophosphate—dependent phosphodiesterase-V inhibitor zaprinast were examined. YC-1 or zaprinast elevated vessel cyclic guanosine monophosphate content, reduced medial wall and neointimal cell proliferation, stimulated medial and neointimal cellular apoptosis, and markedly attenuated neointimal remodeling in comparable fashion. Interestingly, soluble guanylate cyclase inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one failed to noticeably alter neointimal growth, and concomitant zaprinast with YC-1 did not modify any parameter compared to individual treatments. These results provide novel in vivo evidence that YC-1 and zaprinast inhibit injury-induced vascular remodeling through antimitogenic and proapoptotic actions and may offer promising therapeutic approaches against vasoproliferative disorders.